Asset Acquisition - Schedule of Asset Acquisition Cost (Details) - USD ($) $ in Thousands		12 Months Ended
	Jun. 22, 2023	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Asset Acquisition [Line Items]
Acquired in-process research and development		$ 0	$ 0	$ 130,188
Cash acquired		$ 0	$ 0	$ 3,035
Spyre Therapeutics, Inc.
Asset Acquisition [Line Items]
Consideration transferred in Series A Preferred Stock and common stock	$ 110,000
Transaction costs incurred by the Company	3,200
Acquired in-process research and development	130,200
Cash acquired	3,000
Assumed liabilities	(20,000)
Total cost to acquire asset	$ 113,200